Treatment improvement for severe hematological diseases

Research Research programs Treatment improvement for severe hematological diseases

Our mission

We aim to support patients with benign and malignant hematological disorders by deepening our understanding of the underlying pathophysiological mechanisms which will enable us to define novel diagnostic biomarkers for prevention, improved diagnosis and monitoring of these disorders.

Goals

See some of the most important goals for this research program.

Listen

Goals

To unravel the mechanisms of disease and understand the biological consequences.
To improve diagnostic and monitoring modalities and prevent disease progression.
To develop novel forms of precision medicine and perform investigator-initiated phase I/II trials.
To improve quality of life by avoiding treatment-related toxicity and prevent disease progression.
To enhance patient engagement and shared decision-making by offering eHealth-based care platforms.

Research groups contributing to this research program

Experimental hematology

Joop Jansen's research group studies molecular mechanisms of leukemia development with a focus on epigenetic modifiers, splicing factors and transcription factors. In addition, factors influencing clonal evolution in premalignant and malignant states is studied.

Experimental immunology

Annemiek van Spriel's research group studies the immune system at the cellular and molecular level.

Hematology

Nicole Blijlevens's research group wants to develop innovative and effective forms of supportive and integrated care to reduce toxicity and improve tolerability of therapy.

Spokesperson(s) for this research program

Spokesperson

dr. Bert van der Reijden

contact form